What did @jacobzemer actually say?
Zemer laid out a tiered framework for interpreting testosterone levels, rooted in his own experience starting TRT at 400 ng/dL. His core argument: "It's not a health issue. It's not clinically low, but it is a performance issue." He drew a hard line at 300 ng/dL as the clinical threshold for hypogonadism, suggested 500 ng/dL is suboptimal but not dangerous, called 700 ng/dL "a great number especially if you're older," and said 900 ng/dL is the sweet spot where you should "not touch anything." He also briefly mentioned Clomid as a pill alternative to injectable testosterone for men who fall below 300 ng/dL. Throughout, he framed his TRT as a personal performance choice made under physician supervision, not a medical necessity.
Does the science back this up?
Partially. The 300 ng/dL threshold is in the right ballpark, but the framing of these tidy tiers oversimplifies what is actually a messy, symptom-dependent clinical picture. The American Urological Association defines hypogonadism as total testosterone below 300 ng/dL combined with symptoms. The Endocrine Society guidelines (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism) set a similar threshold but emphasize that symptoms, not numbers alone, should drive treatment decisions. A man at 280 ng/dL who feels fine may not need TRT. A man at 420 ng/dL who has low libido, fatigue, and depression might have a real clinical conversation worth having. Zemer's number-only framework skips that nuance entirely. His enthusiasm for 900 ng/dL as an ideal also deserves scrutiny. Reference ranges for adult men typically run from 264 to 916 ng/dL (Travison et al., 2017, Journal of Clinical Endocrinology and Metabolism), so 900 ng/dL sits at the very top of normal, not a universally optimal target.
What did they get wrong (or right)?
Credit where it's due: Zemer correctly identifies 300 ng/dL as a meaningful clinical marker, recommends physician consultation repeatedly, and acknowledges TRT is a personal choice rather than a universal prescription. That's more responsible than most testosterone content on Instagram. However, his tier system treats testosterone numbers like a performance scoring rubric, which is not how endocrinology works. Calling 400 ng/dL "a performance issue" for healthy men is not a clinically established concept. No major guidelines recommend TRT solely for performance optimization in men with testosterone in the normal range. The Testosterone Trials (Snyder et al., 2016, New England Journal of Medicine) studied men over 65 with levels below 275 ng/dL and found modest benefits, not a roadmap for optimizing gym performance in men with normal levels. His framing also risks normalizing TRT as a lifestyle upgrade rather than a treatment for a hormonal disorder, which has real downstream consequences including testicular suppression and fertility effects that go unmentioned.
What should you actually know?
Testosterone levels vary significantly by age, time of day, and lab methodology. A single morning reading is not a diagnosis. Clinical guidelines recommend at least two separate fasting morning measurements before any treatment decision (Bhasin et al., 2018). Symptoms matter as much as numbers. The question isn't just "is my level above 300" but "do I have symptoms consistent with hypogonadism, and have other causes been ruled out." Starting TRT in your 30s or 40s for performance reasons carries real tradeoffs: suppression of the hypothalamic-pituitary-gonadal axis, reduced sperm production, potential cardiovascular effects, and lifetime dependency. The FDA has not approved testosterone for age-related decline or performance optimization in men without diagnosed hypogonadism. Clomid, which Zemer mentions briefly, is used off-label to stimulate endogenous testosterone production and may preserve fertility, which makes it a genuinely different option from exogenous testosterone for some men. That distinction matters and deserved more than a passing mention.